Ag Presenting Cells

📋 Key Information Summary

📋

Antigen presenting cells (APCs) process and display peptide fragments on MHC molecules to activate T lymphocytes — the central event bridging innate and adaptive immunity.
Professional APCs — dendritic cells (DCs), macrophages, and B cells — constitutively express MHC class II and are the primary activators of naïve CD4⁺ T cells.
Dendritic cells are the most potent professional APCs and uniquely capable of priming naïve T cells, making them critical for initiating primary immune responses and vaccine efficacy.
Macrophages serve dual roles as APCs and effector phagocytes; they are prominent in granulomatous inflammation and intracellular pathogen defence (e.g., Mycobacterium tuberculosis).
B cells use the B-cell receptor (BCR) to capture specific antigen at very low concentrations, making them efficient APCs during secondary immune responses and in autoimmune disease.
APC maturation involves upregulation of MHC II, co-stimulatory molecules (CD80/CD86), and cytokine production; immature APCs promote tolerance, while mature APCs drive activation.
T-cell activation requires two signals: Signal 1 (TCR–MHC/peptide) and Signal 2 (CD28–B7 co-stimulation). Without Signal 2, T cells become anergic — the basis of peripheral tolerance.
A third signal (polarising cytokines such as IL-12, IL-4, IL-6, TGF-β) from APCs determines the Th1/Th2/Th17/Treg differentiation fate of activated T cells.
APC dysfunction underlies numerous clinical conditions: immunodeficiency (e.g., bare lymphocyte syndrome type II), autoimmunity, transplant rejection, and tumour immune evasion.
Regulatory mechanisms including CTLA-4, PD-1/PD-L1, and indoleamine 2,3-dioxygenase (IDO) in APCs maintain peripheral tolerance; dysregulation contributes to autoimmune disease in Australians.
Understanding APC biology informs clinical decisions in vaccination strategy, immunosuppression (calcineurin inhibitors block APC-dependent T-cell activation), and emerging immunotherapies (DC vaccines, checkpoint inhibitors).
Aboriginal and Torres Strait Islander Australians experience higher burdens of infections and autoimmune conditions where APC function is critical; culturally safe immunological education is essential.
Current Australian research at WEHI, the Doherty Institute, and Garvan Institute continues to elucidate APC biology for translation into vaccines, cancer immunotherapy, and tolerance induction.

Introduction & Australian Immunological Context

Antigen presenting cells (APCs) are specialised immune cells that capture, process, and display foreign and self-peptides on major histocompatibility complex (MHC) molecules to T lymphocytes. In doing so, they function as the critical bridge between innate and adaptive immunity, initiating, shaping, and regulating the specificity and magnitude of the T-cell response. Without effective antigen presentation, adaptive immunity cannot be appropriately primed, leaving the host susceptible to infection, malignancy, or — paradoxically — autoimmune pathology when presentation becomes dysregulated.

The concept of antigen presentation was first elucidated in the 1970s and 1980s through the work of Zinkernagel and Doherty (Nobel Prize, 1996), who demonstrated MHC-restricted antigen recognition at the John Curtin School of Medical Research in Canberra — a landmark contribution to global immunology from an Australian institution. Subsequent decades of research have defined multiple APC subsets, their maturation pathways, co-stimulatory requirements, and tolerance-promoting functions.

In clinical practice across Australia, APC biology underpins vaccination programmes, management of immunodeficiency states, transplant immunology, cancer immunotherapy, and the understanding of autoimmune diseases that disproportionately affect Australians — particularly type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. A thorough understanding of APC function is therefore essential for clinicians managing these conditions in primary and specialist care.

🏥

Australian research legacy: Peter Doherty (University of Melbourne) shared the 1996 Nobel Prize for discovering MHC restriction of T-cell antigen recognition — the foundational principle of APC immunology.

Types of Antigen Presenting Cells

All nucleated cells express MHC class I molecules and can present endogenous (intracellular) peptides to CD8⁺ cytotoxic T cells — a process termed cross-presentation when performed by specialised APCs on exogenous antigens. However, the term "professional APC" is reserved for cells that constitutively express MHC class II and co-stimulatory molecules, enabling activation of naïve CD4⁺ helper T cells. The three principal professional APCs are dendritic cells, macrophages, and B lymphocytes.

Feature	Dendritic Cells	Macrophages	B Lymphocytes
MHC II expression	Constitutive (high, upregulated with maturation)	Constitutive (inducible by IFN-γ)	Constitutive (moderate)
Co-stimulation (CD80/86)	High (after maturation)	Moderate (induced by TLR ligands)	Moderate (after activation)
Antigen capture mechanism	Macropinocytosis, receptor-mediated endocytosis, phagocytosis	Phagocytosis, FcγR, complement receptors	BCR-mediated (antigen-specific)
Primary role	Initiation of naïve T-cell responses	Effector function + antigen presentation during inflammation	Focused antigen presentation in secondary responses
Cross-presentation	Yes — key function (cDC1 subset)	Limited	Rare
Location (lymph node)	T-cell zones (paracortex)	Subcapsular sinus, medullary cords	B-cell follicles, germinal centres

Dendritic Cells

Dendritic cells (DCs) are the most potent professional APCs and are uniquely capable of activating naïve T cells — a property that places them at the apex of the immune response hierarchy. They originate from bone marrow precursors and exist in two broad functional states: immature DCs residing in peripheral tissues (e.g., Langerhans cells in the epidermis) and mature DCs in secondary lymphoid organs.

DC subsets include:

Conventional DC type 1 (cDC1): Specialised in cross-presentation of exogenous antigens on MHC class I, driving CD8⁺ cytotoxic T-cell responses critical for anti-tumour and anti-viral immunity. Depend on transcription factors BATF3 and IRF8. Key for checkpoint inhibitor efficacy in cancer.
Conventional DC type 2 (cDC2): Present antigens on MHC class II, primarily activating CD4⁺ T helper cells. Drive Th1, Th2, and Th17 responses depending on the cytokine milieu. Depend on IRF4.
Plasmacytoid DCs (pDCs): Produce large quantities of type I interferons (IFN-α/β) in response to viral nucleic acids via TLR7 and TLR9. Less efficient as APCs but critical in anti-viral defence.
Monocyte-derived DCs (moDCs): Differentiate from monocytes during inflammation; abundant at sites of infection and in the synovium of patients with rheumatoid arthritis.

⚠️

Clinical relevance — cancer immunotherapy: DC-based therapeutic vaccines (e.g., sipuleucel-T in prostate cancer) harness the unique ability of DCs to prime tumour-specific T cells. Australian clinical trials at Peter MacCallum Cancer Centre are exploring next-generation DC vaccines for melanoma and other solid tumours.

Macrophages

Macrophages are tissue-resident phagocytes derived from embryonic precursors or circulating monocytes. While their primary function is innate effector activity — phagocytosis, microbicidal killing, and cytokine secretion — they also serve as APCs, particularly in the context of ongoing inflammation and in granulomatous disease.

Macrophage polarisation states relevant to APC function:

M1 (classically activated): Induced by IFN-γ and TLR ligands; produce IL-12, TNF-α, and reactive oxygen/nitrogen species. Promote Th1 responses. Critical in intracellular pathogen defence (Mycobacterium tuberculosis, Leishmania).
M2 (alternatively activated): Induced by IL-4 and IL-13; produce IL-10 and TGF-β. Promote Th2 responses, tissue repair, and fibrosis. Relevant in helminth infections and allergic disease.

In tuberculosis — which has a significant burden in Aboriginal and Torres Strait Islander communities in northern Australia — macrophage APC function is central to granuloma formation and disease containment. Impaired macrophage presentation contributes to disease progression in immunocompromised patients.

B Lymphocytes

B cells function as specialised APCs that use their clonally rearranged B-cell receptor (BCR) to capture specific antigen with extremely high affinity. This allows B cells to concentrate and present antigen at concentrations 1,000–10,000-fold lower than required by DCs or macrophages.

B-cell APC function is particularly important in:

Secondary immune responses: Memory B cells efficiently present recall antigens to memory T cells in germinal centres.
Autoimmune disease: In rheumatoid arthritis and systemic lupus erythematosus, autoreactive B cells present self-antigens to T cells, perpetuating the autoimmune cycle. Rituximab (anti-CD20) depletes B cells and is PBS-listed for refractory RA in Australia.
Viral infections: B cells capture viral particles via BCR and present them to T follicular helper cells, driving affinity maturation and class switching.

Maturation & Activation

APC maturation is the critical transition from a tolerogenic resting state to an immunogenic activated state. This process is triggered by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) acting on pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors.

Step 1

Antigen capture: Immature DCs in peripheral tissues capture antigen via macropinocytosis, receptor-mediated endocytosis (e.g., via C-type lectin receptors such as DC-SIGN and mannose receptor), or phagocytosis of particulate matter and apoptotic cells.

Step 2

PRR signalling & danger detection: Engagement of TLRs (e.g., TLR4 by LPS, TLR3 by dsRNA) or other PRRs triggers NF-κB and MAPK signalling cascades, initiating the maturation programme. This is the "danger signal" that distinguishes pathogenic from innocuous antigen.

Step 3

MHC upregulation & peptide loading: Newly synthesised MHC class II molecules are assembled in the endoplasmic reticulum with the invariant chain (CD74), trafficked to MHC class II compartments (MIICs) for peptide loading, and transported to the cell surface. In immature DCs, MHC II is largely retained intracellularly; maturation triggers surface expression.

Step 4

Co-stimulatory molecule upregulation: Surface expression of CD80 (B7-1), CD86 (B7-2), and CD40 is dramatically increased. These molecules engage CD28 and CD40L on T cells, respectively.

Step 5

Cytokine production: Mature APCs secrete polarising cytokines — IL-12 (Th1), IL-4 (Th2), IL-6 + TGF-β (Th17), TGF-β alone (Treg) — that direct the differentiation fate of activated T cells.

Step 6

Migration to lymph nodes: Maturing DCs downregulate tissue-homing chemokine receptors (CCR1, CCR5, CCR6) and upregulate CCR7, directing migration via afferent lymphatics to T-cell zones of draining lymph nodes where they encounter naïve T cells.

⚠️

Vaccine adjuvant rationale: Aluminium salts (used in Australian National Immunisation Programme vaccines) and newer adjuvants such as AS01 (in Shingrix®) and AS04 (in Cervarix®) work largely by providing danger signals that promote DC maturation, enhancing co-stimulation and antigen presentation to improve vaccine immunogenicity.

Cross-Presentation

Cross-presentation is the ability of certain APCs (primarily cDC1 dendritic cells) to load exogenous antigens onto MHC class I molecules, thereby activating CD8⁺ T cells against pathogens or tumours that do not directly infect APCs. This process is essential for anti-tumour immunity and is a major target of cancer immunotherapy strategies. The cytosolic pathway involves antigen escape from endosomes into the cytosol, proteasomal degradation, and TAP-dependent loading onto MHC I in the ER — mirroring the classical MHC I pathway for endogenous antigens.

Co-stimulatory Signals

T-cell activation requires the integration of multiple signals delivered by APCs. The two-signal model, first proposed by Bretscher and Cohn (1970) and later refined by Lafferty and Cunningham (1975), remains the foundational framework for understanding APC–T-cell interaction.

1

Signal 1 — Antigen Recognition

The T-cell receptor (TCR) engages the peptide–MHC complex on the APC surface. CD4 co-receptor stabilises MHC II interaction; CD8 stabilises MHC I. This signal alone is insufficient for activation and leads to anergy or deletion.

2

Signal 2 — Co-stimulation

CD80/CD86 (B7 family) on the APC engages CD28 on the T cell, providing the essential survival and proliferation signal. Without Signal 2, T cells undergo anergy or apoptosis — a key mechanism of peripheral tolerance.

3

Signal 3 — Polarisation

APC-derived cytokines determine T-cell differentiation: IL-12 → Th1; IL-4 → Th2; IL-6 + TGF-β → Th17; TGF-β → Treg (FoxP3⁺). This "third signal" shapes the effector response.

Key Co-stimulatory and Co-inhibitory Receptor Pairs

APC Ligand	T-cell Receptor	Effect	Clinical Relevance
CD80 / CD86 (B7-1/B7-2)	CD28	Co-stimulation (activation)	Basis of T-cell activation; blocked by abatacept (CTLA-4-Ig, Orencia®) in RA
CD80 / CD86	CTLA-4	Co-inhibition (brake)	Higher affinity than CD28; ipilimumab (anti-CTLA-4) used in melanoma (PBS-authority)
PD-L1 / PD-L2	PD-1	Co-inhibition	Nivolumab, pembrolizumab (anti-PD-1) — PBS-listed for melanoma, NSCLC, RCC
CD40	CD40L (CD154)	Bidirectional — enhances APC function and T-cell help	Critical for germinal centre reactions, B-cell class switching, DC licensing for cross-presentation
ICOS-L	ICOS	T follicular helper cell development	Germinal centre function; deficiency causes common variable immunodeficiency (CVID)
OX40L	OX40 (CD134)	T-cell survival and memory	Target of experimental cancer immunotherapies in Australian trials

🚨

Checkpoint inhibitor adverse events: Disruption of co-inhibitory pathways with anti-PD-1/PD-L1 or anti-CTLA-4 agents can break peripheral tolerance, causing immune-related adverse events (irAEs) — autoimmune thyroiditis, hepatitis, colitis, pneumonitis, and hypophysitis. These require prompt recognition and management with corticosteroids as per eviQ protocols in Australian oncology practice.

Negative Co-stimulation & Immune Checkpoints

Co-inhibitory receptors act as immune checkpoints that prevent excessive T-cell activation and maintain self-tolerance. CTLA-4 is upregulated after T-cell activation and competes with CD28 for B7 ligands with ~20-fold higher affinity. PD-1 is induced on activated T cells and engages PD-L1/PD-L2 expressed by APCs, tumour cells, and stromal cells to deliver an inhibitory signal. Both pathways are exploited therapeutically in Australian cancer care: ipilimumab (anti-CTLA-4) and nivolumab/pembrolizumab (anti-PD-1) are PBS-listed for multiple malignancies under authority prescription.

Lag-3, TIM-3, TIGIT, and VISTA represent emerging co-inhibitory receptors under investigation in combination strategies at Australian cancer centres.

Role in Tolerance

APCs play a dual role: they are essential for immunity but equally critical for establishing and maintaining immune tolerance. Tolerance operates through two main mechanisms — central tolerance (in the thymus and bone marrow) and peripheral tolerance (in tissues and lymph nodes) — and APCs are integral to both.

Central Tolerance

In the thymus, medullary thymic epithelial cells (mTECs) express the transcription factor AIRE (autoimmune regulator), which drives ectopic expression of thousands of tissue-restricted antigens. Developing thymocytes that strongly recognise self-peptide–MHC complexes on mTECs and thymic DCs undergo negative selection (clonal deletion). Mutations in AIRE cause autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED/APS-1), a rare condition seen in Australian paediatric immunology clinics.

Peripheral Tolerance

Peripheral tolerance mechanisms in which APCs participate include:

Mechanism 1

Anergy

Presentation of self-antigen by immature APCs lacking co-stimulatory molecules (low CD80/86) delivers Signal 1 without Signal 2, rendering T cells functionally unresponsive. Tolerogenic DCs are being developed for therapeutic tolerance induction.

Context: Transplant tolerance research (e.g., NHMRC-funded trials at Westmead)

Mechanism 2

Regulatory T-cell Induction

Tolerogenic APCs producing TGF-β and IL-10 promote differentiation of FoxP3⁺ regulatory T cells (Tregs) that suppress autoreactive T cells via CTLA-4, IL-10, TGF-β, and IL-35. Intestinal CD103⁺ DCs in the mesenteric lymph nodes are critical for oral tolerance.

Context: Inflammatory bowel disease, coeliac disease, food allergy

Mechanism 3

Deletion & Exhaustion

Persistent antigen presentation without appropriate co-stimulation leads to activation-induced cell death (AICD) via Fas/FasL interactions or T-cell exhaustion characterised by upregulation of PD-1, LAG-3, and TIM-3. Chronic viral infections (HBV, HCV) and tumours exploit this pathway.

Context: Chronic hepatitis B (high prevalence in ATSI communities), cancer immune evasion

Tolerogenic Dendritic Cells — Therapeutic Potential

Tolerogenic DCs (tolDCs) are generated in vitro by exposing monocyte-derived DCs to immunosuppressive agents (dexamethasone, vitamin D₃, rapamycin) or IL-10. These tolDCs express low MHC II, low CD80/86, and high IL-10/TGF-β, and can induce antigen-specific Tregs and anergy. Clinical trials in rheumatoid arthritis, type 1 diabetes, and solid organ transplantation are underway globally, with Australian centres participating in early-phase studies.

🔬

Australian research: The Immunology and Transplantation laboratories at Westmead Hospital (Sydney) and the Doherty Institute (Melbourne) are conducting NHMRC-funded research on tolDC-based therapies for transplant tolerance and autoimmune disease, including first-in-human trials for type 1 diabetes.

Clinical Relevance for Australian Practice

APC Dysfunction in Immunodeficiency

Primary immunodeficiencies affecting APC function are rare but clinically significant:

Bare lymphocyte syndrome type II (BLS II): Mutations in MHC class II transactivator (CIITA) or promoter elements result in absent MHC class II expression. Patients present in infancy with severe recurrent infections, chronic diarrhoea, and failure to thrive. Diagnosis involves flow cytometry for MHC II expression (available at major Australian immunology centres). Haematopoietic stem cell transplant is the only curative therapy.
IRF8 deficiency: Loss-of-function mutations in IRF8 abolish DC and monocyte development, causing severe immunodeficiency in infancy.
GATA2 deficiency: Monocytopenia and DC deficiency predispose to atypical mycobacterial infections, viral infections (HPV), and myelodysplasia. Seen in Australian adult immunology clinics.
STAT3 loss-of-function (Hyper-IgE syndrome): Impaired Th17 differentiation due to defective APC-derived IL-6/IL-23 signalling, predisposing to mucocutaneous candidiasis and staphylococcal infections.

APCs in Transplant Immunology

APCs are central to allograft rejection through direct and indirect allorecognition:

Direct recognition: Recipient T cells recognise intact donor MHC molecules on donor APCs (passenger leucocytes) within the graft. This drives acute rejection and is the primary target of calcineurin inhibitors (tacrolimus, ciclosporin — PBS-listed).
Indirect recognition: Recipient APCs process shed donor MHC molecules and present donor-derived peptides on self-MHC to recipient T cells. This pathway predominates in chronic rejection.
Semi-direct recognition: Recipient APCs acquire intact donor MHC molecules via extracellular vesicle transfer (trogocytosis), combining features of both pathways.

Immunosuppressive agents used in Australian transplant programmes target APC-dependent pathways: tacrolimus and ciclosporin calcineurin inhibitors block NFAT-dependent IL-2 transcription; mycophenolate inhibits purine synthesis in T and B cells; and belatacept (CTLA-4-Ig) blocks CD80/86 co-stimulation directly.

APCs in Vaccine Immunology

Vaccine efficacy depends on effective APC activation and antigen presentation. Adjuvants used in the Australian National Immunisation Programme enhance DC maturation:

Aluminium salts: Activate NLRP3 inflammasome, promote DC maturation and Th2 skewing (used in Infanrix®, Prevenar 13®, Boostrix®).
AS01 (MPL + QS-21): Activates DCs via TLR4 (MPL) and promotes cross-presentation (used in Shingrix®, Mosquirix®).
mRNA vaccines: Lipid nanoparticles are taken up by DCs at the injection site; mRNA translation produces antigen intracellularly for MHC I and MHC II presentation (Comirnaty®, Spikevax® — COVID-19 programme).

💉

Immunocompromised patients: Patients on immunosuppressive therapy (e.g., methotrexate, biologics) may have impaired DC function and reduced vaccine responses. In Australia, enhanced vaccine schedules and timing adjustments (e.g., vaccination before rituximab) are recommended as per ATAGI and ASCIA guidelines.

Special Populations

👶 Paediatric Considerations

Neonatal DCs

Neonatal DCs produce less IL-12 and are biased toward Th2 responses, contributing to increased susceptibility to intracellular pathogens. This immunological immaturity underpins the vulnerability of neonates to Group B Streptococcus, Listeria, and herpes simplex virus.

Immunisation timing

The Australian NIP schedule (2, 4, 6, 12, 18 months) is designed to account for the maturation of APC–T-cell interactions. Primary series vaccination at these intervals maximises DC-mediated priming and memory generation.

Primary immunodeficiency screening

Absent or markedly reduced MHC class II expression on peripheral blood monocytes (by flow cytometry) should prompt referral to a paediatric immunologist for evaluation of bare lymphocyte syndrome or other APC defects. Available at Sydney Children's Hospital, RCH Melbourne, and Qld Children's Hospital.

🤰 Pregnancy

Trophoblast MHC expression

Trophoblast cells lack classical MHC class I (HLA-A, HLA-B) and MHC class II, preventing maternal T-cell rejection of the semi-allogeneic foetus. They express non-classical HLA-G, which inhibits NK cells and promotes tolerance via interaction with decidual DCs and uterine NK cells.

Decidual DCs and tolerance

Decidual DCs are predominantly tolerogenic (low MHC II, high IL-10), promoting Treg expansion and foetal tolerance. Dysregulation is implicated in pre-eclampsia and recurrent miscarriage — conditions with significant Australian obstetric morbidity.

Vaccination in pregnancy

Influenza and pertussis vaccination (recommended in every pregnancy under NIP) leverage maternal APC activation to generate protective antibody that crosses the placenta, protecting the neonate in the first months of life.

👴 Elderly

Immunosenescence

Ageing is associated with reduced DC numbers (particularly pDCs), impaired migration, decreased TLR signalling, and reduced cross-presentation capacity. This contributes to reduced vaccine efficacy and increased infection susceptibility in Australians aged ≥65 years.

Vaccine implications

High-dose influenza vaccine (Fluzone® High-Dose) and adjuvanted formulations (Fluad® with MF59) are designed to overcome age-related DC impairment. Adjuvanted shingles vaccine (Shingrix®) is recommended for all Australians ≥50 years (NIP-funded from November 2023).

🛡️ Immunocompromised Patients

Biological DMARDs

Anti-TNF agents (adalimumab, infliximab — PBS-listed) impair macrophage APC function and granuloma integrity. Patients on anti-TNF therapy are at increased risk of TB reactivation; pre-treatment screening with TST/IGRA is mandatory in Australia (TGA requirement).

Calcineurin inhibitors

Tacrolimus and ciclosporin block NFAT, suppressing IL-2 production by T cells that are activated by APCs. This reduces both allo- and auto-immune responses but impairs vaccine-induced immunity.

B-cell depleting therapy

Rituximab (anti-CD20) eliminates B cells, including their APC function. Patients should complete vaccinations ≥4 weeks before rituximab initiation where possible (ASCIA recommendation).

🫘 Renal Impairment

Uraemic immunodeficiency

Chronic kidney disease (CKD) stages 4–5 and dialysis are associated with impaired APC function, reduced DC maturation, and defective T-cell activation. This contributes to poor vaccine responses and increased infection risk in the >20,000 Australians on dialysis or with kidney transplants.

Vaccination strategy

Higher or additional vaccine doses may be required for haemodialysis patients. Hepatitis B vaccination with adjuvanted formulations and serological confirmation of response (anti-HBs ≥10 IU/L) is recommended (KHA-CARI guidelines).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Infection burden

Aboriginal and Torres Strait Islander Australians experience significantly higher rates of infections where APC function is critical — including invasive pneumococcal disease, rheumatic heart disease (Group A Streptococcus), tuberculosis (particularly in the Northern Territory), and chronic hepatitis B. Understanding APC-mediated immunity is relevant to managing these conditions.

Autoimmune disease

Rheumatic heart disease — caused by autoimmune cross-reactivity following GAS infection — has a disproportionate burden in Aboriginal and Torres Strait Islander communities, particularly in remote Northern Territory communities. The autoimmune pathogenesis involves APC-mediated activation of cross-reactive T cells targeting cardiac myosin. Rheumatic fever incidence in Indigenous Australians remains >100 per 100,000 in high-risk communities.

Vaccination access

Vaccination coverage gaps persist in remote Aboriginal and Torres Strait Islander communities. ACIR data show lower on-time completion rates for NIP vaccines in some remote areas. Outreach immunisation programmes, Aboriginal Medical Services, and community-controlled health organisations play critical roles in ensuring effective APC-mediated immune priming through timely vaccination.

Environmental factors

Overcrowded housing in remote communities increases exposure to respiratory pathogens, placing greater demands on APC-mediated immune responses. Environmental factors including dust, biomass fuel smoke, and poor nutrition may modulate APC function and mucosal immunity.

Immunological research

Ethical engagement with Aboriginal and Torres Strait Islander communities in immunological research must comply with NHMRC guidelines (Keeping Research on Track II, 2018). Community consultation, cultural safety, and data sovereignty principles must be embedded in all research involving APC biology in these populations. The Lowitja Institute leads Aboriginal and Torres Strait Islander health research governance in Australia.

Clinical implications

Clinicians managing Aboriginal and Torres Strait Islander patients should be aware that the immunological principles governing APC function — including the balance between immunity and tolerance — are universally applicable. Cultural safety in explaining immunological concepts, vaccination rationale, and immunosuppressive therapy decisions should be integrated into care plans. Interpreter services should be used when English is not the patient's first language.

📚 References

1. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974;248(5450):701–702.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–252.
3. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nature Reviews Immunology. 2002;2(2):116–126.
4. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annual Review of Immunology. 2013;31:563–604.
5. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20.
6. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nature Reviews Immunology. 2012;12(8):557–569.
7. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395–1401.
8. Lozano Reina JM, Saidman S, Tullius SG. Tolerogenic dendritic cells in transplantation. Nephrology Dialysis Transplantation. 2015;30(4):530–537.
9. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2022. Available at: immunisationhandbook.health.gov.au.
10. National Health and Medical Research Council (NHMRC). Keeping Research on Track II: A companion document to the NHMRC National Statement on Ethical Conduct in Human Research (2007, updated 2018). Canberra: NHMRC; 2018.
11. AIHW (Australian Institute of Health and Welfare). Aboriginal and Torres Strait Islander Health Performance Framework 2020 summary report. Canberra: AIHW; 2020.
12. RHDAustralia (Rheumatic Heart Disease Australia). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd edition. Darwin: Menzies School of Health Research; 2020.
13. Nutt SL, Chopin M, Wu L. Transcriptional networks driving dendritic cell differentiation and function. Immunity. 2020;52(6):942–956.
14. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery. 2018;8(9):1069–1086.
15. ASCIA (Australasian Society of Clinical Immunology and Allergy). Guidelines for vaccination of the immunocompromised. 2023. Available at: www.allergy.org.au.